These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 3022579)

  • 21. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical guidelines for the use of converting enzyme inhibitors in congestive heart failure.
    Dickstein K
    Int J Cardiol; 1987 Apr; 15(1):1-5. PubMed ID: 3032812
    [No Abstract]   [Full Text] [Related]  

  • 23. [Endothelium--a new target for a therapeutic action of angiotensin-converting enzyme inhibitors].
    Karpov IuA
    Ter Arkh; 2004; 76(6):94-6. PubMed ID: 15332589
    [No Abstract]   [Full Text] [Related]  

  • 24. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C; Cosentino E; De Sanctis D
    Ital Heart J Suppl; 2005 Dec; 6(12):769-79. PubMed ID: 16444921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ACE inhibitors in cardiovascular disease. Which patient? Which drug? Which dose?
    Pellizzer AM; Krum H
    Aust Fam Physician; 1996 Jul; 25(7):1067-9, 1072-3, 1076-7. PubMed ID: 8768273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactions of angiotensin-converting enzyme, kinins and nitric oxide in circulation and the beneficial effects of ACE inhibitors in cardiovascular diseases.
    Magen E; Viskoper RJ
    Isr Med Assoc J; 2000 Dec; 2(12):929-34. PubMed ID: 11344778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Converting enzyme inhibition: implications for renal perfusion and function.
    Hollenberg NK
    Clin Exp Pharmacol Physiol Suppl; 1982; 7():73-9. PubMed ID: 6183037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice.
    Pitt B
    Heart; 2009 Aug; 95(15):1205-8. PubMed ID: 19401281
    [No Abstract]   [Full Text] [Related]  

  • 29. ACE inhibitors in high risk cardiovascular patients: a new hope from the HOPE study.
    Gambhir DS
    Indian Heart J; 2000; 52(2):127-8, 211. PubMed ID: 10893889
    [No Abstract]   [Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolongation of life with angiotensin converting enzyme inhibitor therapy.
    Torp-Pedersen C; Køber L
    Eur Heart J; 2000 Apr; 21(8):597-8. PubMed ID: 10731392
    [No Abstract]   [Full Text] [Related]  

  • 32. ACE inhibitors--revisited.
    Sathyamurthy I; Jayanthi K
    J Assoc Physicians India; 2000 Jul; 48(7):715-8. PubMed ID: 11273508
    [No Abstract]   [Full Text] [Related]  

  • 33. Angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Materson BJ
    Compr Ther; 1983 Oct; 9(10):14-20. PubMed ID: 6196149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the effects of two angiotensin converting enzyme inhibitors, SQ 14 225 and MK 422 in Na-restricted sheep.
    Nelson MA; Stewart KW; Coghlan JP; Denton DA; Fei DT; Scoggins BA
    Clin Exp Pharmacol Physiol Suppl; 1982; 7():87-91. PubMed ID: 6183038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure elucidation of angiotensin converting enzyme inhibitor L-681,176 from Streptomyces sp. MA 5143a.
    Hensens OD; Liesch JM
    J Antibiot (Tokyo); 1984 May; 37(5):466-8. PubMed ID: 6203887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin-converting enzyme inhibitors for cardiovascular therapy: recent advances at the Tenth World Congress of Cardiology Washington DC, September 14-19, 1986.
    Opie LH
    Cardiovasc Drugs Ther; 1987; 1(1):111-2. PubMed ID: 2908699
    [No Abstract]   [Full Text] [Related]  

  • 39. Update on the clinical utility of converting enzyme inhibitors in cardiovascular disease. November 10, 1985, Washington, D.C.
    Am J Med; 1986 Oct; 81(4C):1-50. PubMed ID: 3022579
    [No Abstract]   [Full Text] [Related]  

  • 40. [The clinical use of angiotensin converting enzyme inhibitors].
    Fyhrquist F
    Duodecim; 1986; 102(22):1709-16. PubMed ID: 3026771
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.